BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status
6.4.2022 16:00:00 EEST | Business Wire | Press release
BostonGene today announced the completion of the $150 million Series B funding. NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact Investment Capital and Japan Industrial Partners. The capital will be used to scale BostonGene’s growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC’s robust infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries.
“Many academic and community oncologists across the United States have already adopted BostonGene’s Molecular Portrait Test to improve their patients’ quality of care,” said Takayuki Morita, President and CEO at NEC Corporation. “NEC recently launched a healthcare and life science business unit that utilizes AI and other digital technologies as a key initiative within our 2025 Mid-term Management Plan. We are thrilled to expand on our strategic partnership with BostonGene to advance how physicians treat their patients and dramatically improve clinical outcomes in the U.S., Japan, and the rest of the world.”
“BostonGene has a unique opportunity to build a very large economic value that creates an even larger social impact. That combination is extremely rare, and I am excited and humbled by it,” said Andrew Feinberg, President, and CEO at BostonGene. “This capital positions us well to execute on our vision to enable personalized treatment of cancer patients based on integrated molecular profiles of the tumor, tumor microenvironment, and host immunity.”
BostonGene’s innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system, and the effectiveness of all available approved and investigational treatments. The BostonGene Tumor Portrait™ Tests, a sophisticated analysis of the tumor and tumor microenvironment (TME), reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response to diverse therapies, and recommended therapies. BostonGene’s integrated model of tumor genetics, transcriptomics, microenvironment, and tumor composition provides a 360° overview of a patient tumor to give physicians invaluable insights into potential treatment options.
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes to promote a more sustainable world for everyone. For more information, visit NEC at https://www.nec.com.
About Impact Investment Capital
Impact Investment Capital invests in opportunities with the intention to generate a measurable, beneficial social or environmental impact alongside a financial return.
About Japan Industrial Partners, Inc.
Japan Industrial Partners (JIP) is a private equity firm based in Tokyo, Japan. JIP aims to provide funds and solutions to businesses with significant growth opportunities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005384/en/
Contact information
BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com
NEC
Joseph Jasper
j-jasper@nec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 22:10:00 EEST | Press release
Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build the central nervous system of enterprise security, giving organizations unified visibility and control over their endpoints. During his prior tenure as CEO from 201
Perma-Pipe Secures More Than $67 Million in New Orders in the Second Quarter of 202620.8.2026 20:02:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in engineered piping and corrosion protection solutions, today announced that the Company secured more than $67 million in new orders during the second quarter of fiscal 2026, representing strong demand across its strategically important end-markets and geographies. The orders further strengthen Perma-Pipe's backlog and provide increased visibility into future revenue growth. The Company's backlog remains well diversified across geographies, customers and end-markets. The Company continued to see strong demand across its core Oil & Gas and infrastructure markets, while also securing important new business in emerging applications, including advanced leak detection and monitoring solutions. During the quarter, Perma-Pipe secured sizable Oil & Gas awards in both MENA and Canada, reinforcing the Company's position as a trusted supplier to customers undertaking significant energy infrastructure investments. The Company
Impartner Launches the First CPQ Built for Partners20.8.2026 16:00:00 EEST | Press release
Impartner, the leading partner revenue orchestration platform, today announced the launch ofImpartner CPQ, giving partners a direct path to create and advance quotes within the Impartner PRM platform. The new capability enables faster movement from opportunity to submission while giving vendors control over the rules, products, pricing, and approvals that govern each transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820479441/en/ Give partners a faster path from opportunity to quote with Impartner's CPQ. For many partnership programs, quoting remains a largely manual process. Partners often depend on vendor sales teams to prepare quotes because traditional CPQ systems are designed primarily for direct sellers or require additional licensing for external users. The result is a slower path from opportunity to revenue, increased administrative work for channel teams, and a partner experience that can limit the impa
Scientist.com Expands R&D Platform Capabilities with SciSure’s Integrated LabOps Inventory and Compliance Services20.8.2026 15:55:00 EEST | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, today announced an expansion of its platform capabilities through an integration with SciSure’s lab management and EHS compliance tools. The partnership gives biopharma organizations a more unified workflow connecting scientific procurement directly with laboratory operations. “By bringing SciSure’s inventory management, safety, and compliance capabilities into the Scientist.com ecosystem, we are closing the gap between sourcing reagents and safely managing them in the laboratory,” said Jon Zibell, VP of Global Alliances at SciSure. “Together, our platforms connect product information, safety checks, and inventory management, giving research, lab operations, and EHS teams greater visibility from purchase request through disposal.” The integration connects procurement, safety, inventory, and compliance in a single connected workflow. SciSure enriches Scientist.com’s unified
NETFORCE Accelerates Its U.S. Industrial Expansion as a New Intermediate-Force Market Takes Shape20.8.2026 15:23:00 EEST | Press release
For the first time, major U.S. federal agencies are beginning to structure procurement around a new category of intermediate-force equipment, giving officers an additional option between verbal presence and higher levels of force. NETFORCE believes companies establishing themselves at this early stage will benefit from a significant first-mover advantage as this category expands nationwide. This is precisely the market NETFORCE anticipated years ago, having invested heavily in research, industrialization and international intellectual property well before the category attracted attention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820951658/en/ COPYRIGHT NETFORCE NETFORCE enters the U.S. market backed by two granted and active U.S. patents — US 11,236,973 B2 (granted 2022, protected through 2038) and US 12,222,193 B2 (granted 2025, protected through 2041). Together with the E-StunGlove® trademark, these assets form pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom